

June 19, 2020

To,  
National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001

Dear Sirs,

**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

--0--

Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are filing herewith Disclosure of Related Party Transactions during the half year ended on March 31, 2020 on a consolidated basis, in the format specified in the accounting standards, and the same is also available on the website of the Company viz, [www.thyrocare.com](http://www.thyrocare.com).

Please take the same on record.

Yours Faithfully,

For Thyrocare Technologies Limited,

**Ramjee Dorai**  
**Company Secretary and Compliance Officer**



Thyrocare Technologies Limited

# Thyrocare Technologies Limited

## Notes to the consolidated financial statements

for the half year ended 31 March 2020

Currency : In crore of INR

### 38 Related parties

Description of relationship	Names of related parties
<i>Associates</i>	Equinox Labs Private Limited (From 28 March 2018) Thyrocare International Holding Company Limited, Mauritius (liquidated during the year ended 31 March 2020)
<i>Enterprise over which directors and their relatives exercise control or influence, where transactions have taken place during the year</i>	Thyrocare Gulf Laboratories WLL Sumathi Healthcare Private Limited * (Previously known as Sumathi Construction Private Limited) Pavilion Commercial Private Limited Sumathi Infra Project LLP Mahima Advertising LLP Thyrocare Publications LLP Thyrocare Properties & Infrastructure Private Limited Sumathi Memorial Trust
<i>Key Management Personnel (KMP)</i>	Dr A Velumani, Managing Director A Sundararaju, Director Anand Velumani, Director Amruta Velumani, Director
<i>Relatives of KMP</i>	Dr A Velumani HUF (HUF in which Dr A Velumani is Karta) A Sundararaju HUF (HUF in which A Sundararaju is Karta) S Susila (sister of Dr A Velumani)

#### B. Transactions with key management personnel

##### i. Key management personnel compensation


	Transaction value Half Year ended 31 March 2020	Balance outstanding Half Year ended 31 March 2020
Dr A Velumani	(0.00)*	0.00
A Sundararaju	0.25	-
	<u>0.25</u>	<u>0.00</u>

\* Amount less than Rs. 1 lakh

As the liabilities for defined benefit plans are provided on actuarial basis for the Company as a whole, the amount pertaining to key managerial personnel are not included.

##### ii. Transactions with key management personnel including directors

	Transaction value Half Year ended 31 March 2020	Balance outstanding Half Year ended 31 March 2020
<i>Dividend paid</i>		
Dr A Velumani	7.40	-
A Sundararaju	0.12	-
Amruta Velumani	0.38	-



# Thyrocare Technologies Limited

## Notes to the consolidated financial statements for the half year ended 31 March 2020

Currency: In crore of INR

### C. Related party transaction other than those with key management personnel

	Transaction value Half Year ended 31 March 2020	Balance outstanding Half Year ended 31 March 2020
<i>Rent Paid / payable</i>		
Sumathi Healthcare Private Limited *	-	-
<i>Outlab processing charges paid / payable</i>		
Equinox Labs Private Limited	0.02	0.03
<i>Payment of lease liabilities</i>		
Sumathi Healthcare Private Limited *	0.64	
<i>Loan taken from</i>		
Pavilion Commercial Private Limited	-	2.50
<i>Interest paid</i>		
Pavilion Commercial Private Limited	0.11	
<i>Revenue from operations</i>		
Thyrocare Gulf Laboratories WLL	2.15	2.53
Sumathi Memorial Trust (refer note)	1.65	1.19
<i>Receipt on liquidation of investment</i>		
Thyrocare International Holding Company Ltd, Mauritius	0.03	
<i>Loss on liquidation of investment (for which provision made in earlier years)</i>		
Thyrocare International Holding Company Ltd, Mauritius	1.59	
<i>Provision for doubtful trade receivables</i>		
Thyrocare Gulf Laboratories WLL	1.62	2.27
<i>Reimbursement of expenses paid</i>		
Thyrocare Gulf Laboratories WLL	0.17	
Sumathi Healthcare Private Limited *	0.19	
<i>Reimbursement of expenses received</i>		
Sumathi Healthcare Private Limited *	0.73	
<i>Technical assistance fees income</i>		
Thyrocare Gulf Laboratories WLL	0.53	
<i>Dividend paid</i>		
Anand Velumani	0.32	
Dr A Velumani HUF	0.71	
A Sundararaju HUF	1.21	
Sumathi Infra Project LLP	0.79	
Mahima Advertising LLP	0.63	
Thyrocare Properties & Infrastructure Private Limited	2.61	
Thyrocare Publications LLP	3.27	
<i>Advances received towards sale of property</i>		
Sumathi Healthcare Private Limited *	-	25.00
<i>Investment in equity instruments (At historical cost)</i>		
Equinox Labs Private Limited	-	20.00
<i>Security deposits given/ (repaid)</i>		
Sumathi Healthcare Private Limited *	-	1.54

\* Formerly known as Sumathi Construction Private Limited

Notes :



# Thyrocare Technologies Limited

## Notes to the consolidated financial statements

for the half year ended 31 March 2020

Currency: In crore of INR

- i. The key management personnel, or their related parties, hold position in other entities that result in them having control or significant influence over these entities. These entities transacted with the Company during the reporting period. The terms and conditions of the transactions with key management personnel and their related parties were at arm's length and in the normal course of the business.
- ii. Sumathi Memorial Trust, a charitable trust managed by the promoters of the Company as trustees, in tie up with other NGO subsidised the cost of PET-CT scans for the cancer patients who can not afford the cost of the PET-CT scan, by direct payment to the Company cost of PET-CT scans towards such cancer patients.

